- Home
- DSGN vs GF Comparison
DSGN vs GF Comparison
Compare DSGN & GF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- GF
- Stock Information
- Founded
- DSGN 2017
- GF 1990
- Country
- DSGN United States
- GF Germany
- Employees
- DSGN N/A
- GF N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- GF Investment Managers
- Sector
- DSGN Health Care
- GF Finance
- Exchange
- DSGN Nasdaq
- GF Nasdaq
- Market Cap
- DSGN 208.9M
- GF 192.4M
- IPO Year
- DSGN 2021
- GF N/A
- Fundamental
- Price
- DSGN $5.26
- GF $11.67
- Analyst Decision
- DSGN
- GF
- Analyst Count
- DSGN 0
- GF 0
- Target Price
- DSGN N/A
- GF N/A
- AVG Volume (30 Days)
- DSGN 141.5K
- GF 28.1K
- Earning Date
- DSGN 08-07-2025
- GF 01-01-0001
- Dividend Yield
- DSGN N/A
- GF 0.82%
- EPS Growth
- DSGN N/A
- GF N/A
- EPS
- DSGN N/A
- GF N/A
- Revenue
- DSGN N/A
- GF N/A
- Revenue This Year
- DSGN N/A
- GF N/A
- Revenue Next Year
- DSGN N/A
- GF N/A
- P/E Ratio
- DSGN N/A
- GF N/A
- Revenue Growth
- DSGN N/A
- GF N/A
- 52 Week Low
- DSGN $2.60
- GF $7.38
- 52 Week High
- DSGN $7.77
- GF $9.41
- Technical
- Relative Strength Index (RSI)
- DSGN 61.90
- GF 43.84
- Support Level
- DSGN $4.68
- GF $11.55
- Resistance Level
- DSGN $5.60
- GF $11.89
- Average True Range (ATR)
- DSGN 0.39
- GF 0.20
- MACD
- DSGN 0.04
- GF -0.03
- Stochastic Oscillator
- DSGN 79.95
- GF 11.54
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.